Form 4: 10x Genomics CEO Sells Shares for Tax Obligations

10x Genomics CEO Serge Saxonov sold 13,261 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Serge Saxonov, CEO and Director of 10x Genomics, Inc. (TXG), reported a sale of Class A Common Stock.
• The transaction involved the disposition of 13,261 shares at a price of $18.9983 per share.
• The sale, which occurred on November 24, 2025, was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Saxonov directly beneficially owns 1,021,556 shares of Class A Common Stock.
• Additionally, Mr. Saxonov indirectly beneficially owns 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, for which he serves as trustee.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale to cover tax obligations upon RSU vesting, which is a common occurrence for executives and generally considered neutral in terms of market sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is an insider transaction report, which is a routine disclosure for executives and directors. It does not provide insights into broader industry trends or competitive landscape, but rather details a personal stock transaction by a key executive.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-planned transaction for tax purposes and not indicative of a change in management's confidence in the company's fundamentals.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, Insider Sale, Form 4, CEO, Stock Sale, Tax Withholding, RSU Vesting, Biotechnology